icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm
27 Jan, 2018 11:35

Carillion, the NHS & profit-hungry big pharma? (E567)

We ask former UK Shadow Emergencies Minister Chris Williamson MP why his party countenanced signing deals with Carillion. Director of NGO Global Justice Now urges a future British Labour government to atone for its sins. Plus, UK PM Theresa May slams Jeremy Corbyn's Labour Party for its track record in healthcare at this week's PMQs.


Going Underground http://fb.me/GoingUndergroundRT

Going Underground https://www.youtube.com/user/GoingUndergroundRT
Going Underground on Twitter http://twitter.com/Underground_RT
Afshin Rattansi on Twitter http://twitter.com/AfshinRattansi
on Instagram http://instagram.com/officialgoingundergroundrt

The science behind alemtuzumab was established at the University of Cambridge in the seventies. Subsequently, the commercial development rights were licensed out to several different companies for over 20 years, with revenue flowing back to the university. 

Upon acquiring the developmental responsibilities for alemtuzumab Sanofi Genzyme funded an extensive multicentre, multi-country, clinical development programme in which more than 1,500 patients participated (900 of whom received alemtuzumab) to demonstrate the clinical benefits and MS-specific dosing. It was our investment that enabled the impact of alemtuzumab to be seen beyond its first indications (including Chronic Lymphocytic Leukaemia or CLL). This also then achieved a European licence to treat adults with relapsing-remitting multiple sclerosis (RRMS) in 2013.

Following this, NICE (the National Institute for Health and Care Excellence) and SMC (Scottish Medicines Consortium) appraised alemtuzumab (brand name: Lemtrada) and concluded that it is a cost-effective use of NHS resources for treating adults with active RRMS. On recommending Lemtrada for use in the NHS, NICE Chief Executive, Sir Andrew Dillon said: “We are very pleased to be able to recommend alemtuzumab for adults with relapsing-remitting multiple sclerosis. Evidence has shown that alemtuzumab is more effective and less expensive than current similar treatments for those with severe relapsing-remitting MS.” 

It is important to note that the dosing for alemtuzumab in multiple sclerosis is unique in that it is not taken daily, weekly or monthly, but recommended as two courses, 12 months apart (5-day course in the first month, followed by a 3-day course a year later). The cost of alemtuzumab are mainly incurred at the beginning of treatment as it is not taken regularly. Therefore, its direct medication costs over a lifetime will be lower compared with some other MS treatments. 

In the process of this development, the licence for CLL was not renewed, however Sanofi Genzyme introduced a patient access programme, enabling patients for whom alternative treatments for CLL are not an option to receive alemtuzumab free of charge. This programme has benefitted tens of thousands of patients globally to date.

As an organisation, we are committed to making a difference to patients’ daily life. Investing more than €5 billion annually in research and development, we continue to focus on delivering significant advances in the treatment of MS and other diseases.